टेनोफोविर-आधारित मौखिक PrEP लेने वाले रोगी में तीव्र HIV संक्रमण का उपचार

References

1. There is a greater possibility that HIV drug resistance mutations may emerge and reduce the efficacy of an initial ART regimen in patients with a new reactive HIV screening test or a new HIV diagnosis who have taken tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or tenofovir alafenamide fumarate/emtricitabine (TAF/FTC) as PrEP since their last negative HIV test result.
2. For such patients, the initial regimen should consist of an integrase strand transfer inhibitor (INSTI) with a high barrier to resistance (e.g., DTG or bictegravir [BIC] or boosted DRV) and 2 nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs).
3. The initial regimen may be simplified once results of baseline genotypic testing have been reviewed.
4. The clinicians should implement treatment to suppress the patient's plasma HIV RNA to below detectable levels.
5. Clinicians should obtain a viral load test 4 weeks after ART initiation to assess the response to therapy.